AbCellera Q1 2023 revenue $12M, net loss $0.14 EPS vs $0.59 EPS profit in Q1 2022

AbCellera Biologics Inc.

2023-Q1 EPS reported -$0.14 revenue$12,192,000

Total revenue $12.2M, down from $316.6M in Q1 2022; net loss $40.1M vs net income $168.6M.
EPS loss $0.14 basic/diluted versus EPS profit $0.59 basic/0.54 diluted a year ago.
Partnered program starts reached 101 cumulative (up 20% YoY); 9 molecules in clinic (up from 6).
R&D spending rose to $52.6M from $26.4M; cash and marketable securities $821.5M.
Management highlighted T-cell engager platform progress; no guidance provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.